Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fresenius Kabi Oncology

- PMLiVE

EMA refuses to back Pfizer’s Xeljanz in rheumatoid arthritis

Surprise after approvals in US and Japan

- PMLiVE

Novo Nordisk launches new US insulin campaign

US IndyCar driver, diabetic and FlexPen user Charlie Kimball fronts activities

- PMLiVE

Novo opens doors on new US headquarters

$225m redevelopment for New Jersey life science offices

- PMLiVE

European drug applications ‘stable but more complex in 2012’

Despite austerity measures, EMA's annual report shows signs of biopharma resilience

- PMLiVE

AstraZeneca signs $200m deal with Bind for cancer drug

Follows deals with Amgen and Pfizer for Bind involving its Accurin nanotechnology

- PMLiVE

Roche faces another NICE rejection for Avastin

Draft guidance turns down drug for use in ovarian cancer

- PMLiVE

EMA recommends heart risk restriction for Servier’s Protelos

Use of osteoporosis drug likely to be further tightened up

- PMLiVE

Sanofi’s four-strain flu vaccine Vaxigrip under review in EU

Pharma company also launches production of ingredient for malaria drug

- PMLiVE

US-based Millennium launches blood cancer website

The Takeda Oncology Company roll out new multiple myeloma website

- PMLiVE

Clinical trials for EMA-submitted medicines move away from US and Europe

Most trial patients for drug marketing applications to EMA now come from rest of the world

- PMLiVE

Gilead files oral hepatitis C drug sofosbuvir in US

Could be part of first all-oral regimen for virus

Unfolding the biosimilar landscape in Latin America

Cost containment and safety concerns mean an ongoing tussle between payers and regulators, with the latter gaining the upper hand

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links